Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (5): 812-814    DOI: 10.12891/ceog5179.2019
Case Report Previous articles | Next articles
The increased cellular permeability syndrome manifesting as severe idiopathic type urinary incontinence
J.H. Check1, 2, *(), D. Check2
1Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ, USA
2Cooper Institute for Reproductive Hormonal Disorders, P.C. Mt. Laurel, NJ, USA
Download:  PDF(180KB)  ( 229 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose: To evaluate the efficacy of treatment with dextroamphetamine sulfate for severe idiopathic urgency urinary incontinence refractory to treatment with the selective beta 3 adrenergic agonist, mirabegron. Materials and Methods: Dextroamphetamine sulfate extended release capsule was started at 9.4 mg and increased to 15.7 mg in a woman with two years of severe urgency urinary incontinence. Results: The urgency urinary incontinence completely resolved, as did the fibromyalgia, headaches, and chronic fatigue syndrome. The symptoms have remained eradicated for over one year while treatment continues. Conclusions: Idiopathic urgency urinary incontinence (neurogenic bladder) has been found to be another manifestation of the increased cellular permeability syndrome. Similar to the other chronic disorder associated with the increased cellular permeability syndrome, idiopathic urgency urinary incontinence responds well to dextroamphetamine sulfate treatment despite failure to respond to standard therapy.

Key words:  Idiopathic urgency urinary incontinence      Neurogenic bladder      Dextroamphetamine sulfate      Increased cellular permeability syndrome      Dopamine     
Published:  10 October 2019     
*Corresponding Author(s):  J.H. CHECK     E-mail:  laurie@ccivf.com

Cite this article: 

J.H. Check, D. Check. The increased cellular permeability syndrome manifesting as severe idiopathic type urinary incontinence. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 812-814.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog5179.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I5/812

[1] J.H. Check, D. Check, R. Cohen. A novel effective treatment for menière’s disease – dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 807-809.
[2] H. Kwon, J.E. Shin, H. Kim. A novel treatment of severe dysmenorrhea due to adenomyosis: a case series of 3 infertile patients treated with dopamine agonist and in vitro fertilization-embryo transfer resulting in successful pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 637-640.
[3] J.H. Check, R. Cohen. Sympathomimetic amine therapy abrogates severe long-term unexpalined abdominal pain and diarrhea (microscopic colitis) - possible infertility implications[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 489-491.
[4] J.H. Check, D.L. Check, M.P. Dougherty. Marked improvement of the aromatase induced arthralgia syndrome following treatment with dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 291-292.
[5] J.H. Check, M.P. Dougherty, D.L. Check. Long standing post-herpetic neuralgia resistant to standard anti-neuropathy medication showing quick dramatic improvement following treatment with sympathomimetic amines[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 335-336.
[6] J.H. Check, M. Citerone, T. Citerone. The increased cellular permeability syndrome as a cause of traumatic stuttering[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 773-774.
[7] J.H. Check. Changing the name of a syndrome: sympathetic neural hyperalgesia edema syndrome becomes – the increased cellular permeability syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 819-823.
[8] J.H. Check, R. Cohen. Amelioration of severe generalized idiopathic pruritus in an estrogen deficient woman taking an aromatase inhibitor for breast cancer following treatment with amphetamine salts[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 934-935.
[9] J. H. Check, R. Cohen. Marked improvement of severe gastroparesis following high dosage, but very well tolerated, dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(4): 611-612.
[10] J.H. Check, A. Jaffe. Dextroamphetamine sulfate provided quick relief of severe post-partum depression that was recalcitrant to standard antidepressants and psychotherapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 272-274.
[11] J.H. Check. Chronic unremitting lower abdominal pain quickly abrogated following treatment with amphetamine[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(1): 109-111.
[12] A.C. Collier, B.L.M. Sato, K.A. Milam, T.E. Wright. Methamphetamine, smoking, and gestational hypertension affect norepinephrine levels in umbilical cord tissues[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(5): 580-585.
[13] J.H. Check, A. Jaffe. Resolution of pelvic pain related to adenomyosis following treatment with dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(5): 671-672.
[14] J.H. Check, B. Katsoff. Transient sixth cranial nerve palsy following orgasm abrogated by treatment with sympathomimetic amines[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(4): 468-470.
[15] J.H. Check, R. Cohen. Sympathomimetic amine therapy found effective for treatment of refractory chronic complex regional pain syndrome (reflex sympathetic dystrophy)[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(4): 478-482.
No Suggested Reading articles found!